 |
|
|
| |
HIV Coinfection Impairs the Response to DAA-based HCV Therapy
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Karin Neukam1,2, Marta Suárez-Santamaría4, Antonio Rivero-Juárez3, Alberto Romero-Palacios5, Enrique Ortega6, Ignacio de los Santos-Gil7, Josep Cucurull8, Francisco Vera-Mendez9, Juan A Pineda1
and Grupo de Estudio de Hepatitis Vírica, of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica: GEHEP-SEIMC and HEPAVIR Study Group of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI) / Red de Investigación en SIDA (RIS-HEP07)
1Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Seville, 2Unit of Infectious Diseases, Hospital Universitario Alvaro Cunqueiro, Vigo, 3Unit of Infectious Diseases, Reina Sofía University Hospital, Maimónides Institute of Biomedical Investigation. University of Cordoba (IMIBIC), Cordoba, 4Unit of Infectious Diseases, Hospital Universitario Puerto Real, Puerto Real, 5Unit of Infectious Diseases, Hospital General Universitario de Valencia, Valencia, 6Unit of Infectious Diseases, Hospital Universitario de la Princesa, Madrid, 7Service of Internal Medicine, Hospital de Figueres-Fundació Salut Empordà, Figueres, 8Service of Internal Medicine, Hospital General Universitario Santa Lucía, Cartagena, Spain
from Jules: in Figure 1 there were 13 coinfected vs 6 mono infected who experienced viral breakthrough (1 vs 0), relapse (5 vs 2), discontinuation due to AE (1 vs 1), voluntary dropout (3 vs 1), and LFTU or death (3 vs 1).
|
| |
|
|
|
|
|
